OptimizeRx (OPRX) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue grew 14% year-over-year to $32.3M; full-year revenue up 29% to $92.1M, beating guidance and Street expectations.

• New CEO outlined a strategic focus on operational excellence, customer centricity, and recurring revenue growth, aiming to become a Rule of 40 company over the next 3–5 years.

• Completed a strategic review, confirming the company is on the right path for growth and transformation, with a focus on transitioning DAAP customers to subscription-based models.

• Company executed 48 DAAP deals in 2024, doubling from 24 in 2023.

Financial highlights

• Q4 2024 revenue was $32.3M, up 14% year-over-year, driven by increased DAAP-related revenue.

• Gross margin rose to 68.2% in Q4 2024 from 62.9% in Q4 2023, attributed to favorable solution and channel partner mix.

• Q4 2024 net loss was $0.1M, improved from a $4.1M net loss in Q4 2023; non-GAAP net income was $5.5M ($0.30/share) vs. $4.6M ($0.26/share) prior year.

• Adjusted EBITDA for Q4 2024 was $8.8M, up from $5.8M in Q4 2023; full-year Adjusted EBITDA $11.7M.

• Year-end cash and short-term investments totaled $13.4M; net cash from operating activities was $4.9M for 2024.

Outlook and guidance

• 2025 revenue expected to be at least $100M, with Adjusted EBITDA of at least $12M, margin ramping up in the back half of the year.

• Targeting a three- to five-year journey to achieve Rule of 40, with most improvement expected from EBITDA expansion and some from top-line growth.

• 2025 guidance reflects typical seasonality: 15–20% of revenue in Q1, 20–23% in Q2, 25–30% in Q3, and 30–40% in Q4.

• Net revenue retention targeted at 100% for 2025, with 5–20% of business expected from new logos.

• Gross margin expected in the high 50s to mid-60% range, with Q4 levels seen as aspirational but not sustainable year-round.